Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

    SBC: IQ Medical Imaging LLC            Topic: 102

    Project SummaryAbstract Tumor imaging quantification is critical for diagnosisstagingand treatment evaluationand multi detector CTMDCTis the clinical imaging modality commonly used for patients diagnosed with hepatic malignancy because of its relatively low cost and wide availabilityConventional tumor quantification using either linear or volumetric measurement has demonstrated significant limitat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Advancing a novel portable detection method for cannabis intoxication

    SBC: Brain Solutions, LLC            Topic: NIDA

    TBD

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses

    SBC: IQ Medical Imaging LLC            Topic: 102

    Project SummaryAbstract The neurofibromatosesNFsincluding NFNFand schwannomatosisare a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtuallyof patients to develop multiple nerve sheath tumorsThe determination of tumor burden on magnetic resonance imagingMRIis indispensable for the longitudinal management of NF patientswhich includes life long follow up f ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government